🇺🇸 FDA

Intelligence Platform

Patents

Browse 454 pharma-relevant US patents (A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 9155775

Process for manufacturing glatiramer acetate product

TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue Oct 13 2015 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 08 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9149468

Multicomponent crystals made ([2-amino-6-(4-fluoro-benzylamino)-pyridin-3-yl]-carbamic aci

TEVA GmbH · Granted Tue Oct 06 2015 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 01 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9139525

N-oxide and/or di-N-oxide derivatives of dopamine receptor stabilizers/modulators displayi

TEVA PHARMACEUTICALS INTERNATIONAL GMBH · Granted Tue Sep 22 2015 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 17 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9127057

Anti-IL-23 heterodimer specific antibodies

TEVA PHARMACEUTICALS AUSTRALIA PTY LTD · Granted Tue Sep 08 2015 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 03 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9107832

Risperidone microparticles formed by sublimation

TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue Aug 18 2015 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 13 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9102620

Deuterated N-ethyl-N-phenyl-1,2-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carbo

TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue Aug 11 2015 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 06 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9090598

Nilotinib salts and crystalline forms thereof

TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue Jul 28 2015 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 23 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9066957

Dry powder inhaler

Teva Branded Pharmaceutical Products R&D, Inc. · Granted Tue Jun 30 2015 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 25 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9063153

Cytokine biomarkers as predictive biomarkers of clinical response for glatiramer acetate

TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue Jun 23 2015 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 18 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9018170

Reduced volume formulation of glatiramer acetate and methods of administration

TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue Apr 28 2015 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 23 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9012641

Crystalline forms of Prasugrel salts

TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue Apr 21 2015 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 16 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8993519

Method of treatment for neutropenia using stable formulations of recombinant human albumin

TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue Mar 31 2015 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 26 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8987216

Polysulfated glycosides and salts thereof

Teva Hungary Pharmaceutical Marketing Private Limited Company · Granted Tue Mar 24 2015 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 19 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8980304

Barrel-shaped vaginal ring

TEVA WOMEN'S HEALTH, INC. · Granted Tue Mar 17 2015 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 12 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8975279

Amine salts of laquinimod

TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue Mar 10 2015 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 05 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8975442

Process for the preparation of and crystalline forms of optical enantiomers of modafinil

Teva Sante · Granted Tue Mar 10 2015 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 05 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8962847

Multicomponent crystals made of ([2-amino-6-(4-fluoro-benzylamino)-pyridin-3-yl]-carbamic

TEVA GmbH · Granted Tue Feb 24 2015 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 19 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8946300

Use of rasagilline for the treatment of restless legs syndrome

TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue Feb 03 2015 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 29 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8946167

Pharmaceutical compositions containing plasma protein

TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue Feb 03 2015 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 29 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8937082

Nilotinib salts and crystalline forms thereof

TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue Jan 20 2015 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 15 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8932588

Treatment of cancer involving mutated KRAS or BRAF genes

TEVA PHARMACEUTICALS AUSTRALIA PTY LTD · Granted Tue Jan 13 2015 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 08 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8920373

Reduced volume formulation of glatiramer acetate and methods of administration

TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue Dec 30 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 25 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8901279

Humanized antibodies with anti-tumor activity

TEVA PHARMACEUTICALS AUSTRALIA PTY LTD · Granted Tue Dec 02 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 27 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8889661

Treatment of lupus nephritis using laquinimod

TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue Nov 18 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 13 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

granted